Skip to main content

Table 1 Summary of demographics of patients with and without NACT

From: Reconstructive outcome analysis of the impact of neoadjuvant chemotherapy on immediate breast reconstruction: a retrospective cross-sectional study

Variable

All

(n = 269)

NACT (%)

(n = 46)

Non-NACT (%)

(n = 223)

p value

Mean age at diagnosis ± SD, year

44.3 ± 8.2

40.9 ± 7.4

45.0 ± 8.2

0.002*

Mean BMI ± SD, kg/m2

22.9 ± 3.7

22.8 ± 3.2

22.9 ± 3.8

0.892

History of smoking

5 (1.9)

1 (2.2)

4 (1.8)

1.000

Hypertension

13 (4.8)

0 (0.0)

13 (5.8)

0.134

Diabetes mellitus

3 (1.1)

1 (2.2)

2 (0.9)

0.432

Stage

 T stage

   

1.000

  T0-T1

95 (35.3)

30 (65.2)

144 (64.6)

 

  T2-T4

174 (64.7)

16 (34.8)

79 (35.4)

 

 N stage

   

0.042*

  N0†

187 (69.5)

25 (54.3)

162 (72.6)

 

  N1†

62 (23.0)

16 (34.8)

46 (20.6)

 

  N2-N3

20 (7.4)

5 (10.9)

15 (6.7)

 

 Pathological stage

   

< 0.001*

  0†

52 (19.9)

0 (0.0)

52 (23.3)

 

  I

85 (32.6)

12 (31.6)

73 (32.7)

 

  II

98 (37.5)

19 (50.0)

79 (35.4)

 

  III

26 (10.0)

7 (18.4)

19 (8.5)

 

Histological type

 IDC†

167 (62.1)

39 (84.8)

128 (57.4)

< 0.001*

 ILC

21 (7.8)

1 (2.2)

20 (9.0)

0.141

 DCIS†

109 (40.5)

0 (0.0)

109 (48.9)

< 0.001*

 LCIS

3 (1.1)

0 (0.0)

3 (1.3)

1.000

 Other

32 (11.9)

4 (8.7)

28 (12.6)

0.619

pCR

 

8 (17.4)

  

 Estrogen receptor positive

217 (81.0)

37 (80.4)

180 (81.1)

1.000

 Progesterone receptor positive

206 (76.9)

34 (73.9)

172 (77.5)

0.571

 TNBC/HER-2 positive

86 (32.0)

23 (50.0)

63 (28.3)

0.005*

  HER-2 amplified

73 (27.3)

20 (43.5)

53 (24.0)

0.010*

  Triple negative breast cancer

13 (4.8)

3 (6.5)

10 (4.5)

0.471

Post-mastectomy radiotherapy

52 (19.3)

30 (65.2)

22 (9.9)

< 0.001*

Adjuvant chemotherapy

150 (59.1)

32 (69.6)

127 (57.0)

0.139

Adjuvant hormone therapy

203 (75.5)

35 (76.1)

168 (75.3)

1.000

Local recurrence

1 (0.4)

0 (0.0)

1 (0.4)

1.000

Distant metastasis

16 (5.9)

9 (19.6)

7 (3.1)

< 0.001*

Interval between NACT and surgery, week

 

4.8 ± 2.6

  

Mean follow-up ± SD, month

46.3 ± 32.2

35.0 ± 28.5

48.6 ± 32.5

0.009*

  1. NACT neoadjuvant chemotherapy, SD standard deviation, BMI body mass index, pCR pathological complete response
  2. †The adjusted standardized residual was greater than 2 which indicates the column proportions were significantly different at p < 0.05 level
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us